Michael Staehler

22.4k total citations · 4 hit papers
266 papers, 11.6k citations indexed

About

Michael Staehler is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Michael Staehler has authored 266 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 215 papers in Pulmonary and Respiratory Medicine, 102 papers in Molecular Biology and 75 papers in Cancer Research. Recurrent topics in Michael Staehler's work include Renal cell carcinoma treatment (196 papers), Renal and related cancers (95 papers) and Cancer Genomics and Diagnostics (71 papers). Michael Staehler is often cited by papers focused on Renal cell carcinoma treatment (196 papers), Renal and related cancers (95 papers) and Cancer Genomics and Diagnostics (71 papers). Michael Staehler collaborates with scholars based in Germany, United States and France. Michael Staehler's co-authors include Axel Bex, Börje Ljungberg, Saeed Dabestani, Thomas Lam, Lorenzo Marconi, Fabian Hofmann, Alessandro Volpe, Karim Bensalah, Thomas Powles and Markus A. Kuczyk and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Michael Staehler

253 papers receiving 11.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

2015 2.1k citations Börje Ljungberg, Karim Bensalah et al. profile →
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

2019 1000 citations Börje Ljungberg, Karim Bensalah et al. profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy

2015 380 citations Lorenzo Marconi, Saeed Dabestani et al. profile →

Peers

Countries citing papers authored by Michael Staehler

Since Specialization

Citations

This map shows the geographic impact of Michael Staehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Staehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Staehler more than expected).

Fields of papers citing papers by Michael Staehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Staehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Staehler. The network helps show where Michael Staehler may publish in the future.

Co-authorship network of co-authors of Michael Staehler

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Staehler. A scholar is included among the top collaborators of Michael Staehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Staehler. Michael Staehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma 2025 ·Ulka N. Vaishampayan, Sumanta K. Pal, (unknown), Neha D. Shah, Dena Battle, Michael Staehler	0
2	Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma 2025 ·Cancers ·(unknown), Adrien Holzgreve, Marcus Unterrainer, (unknown), Hans Peter Schmid, Michael Schöll, (unknown), (unknown), (unknown), Jozefina Casuscelli, Alexander Tamalunas, Rudolf A. Werner, Christian G. Stief, Michael Staehler, Lena M. Unterrainer	0
3	Real world data on treatment of chromophobe renal cell carcinoma. 2024 ·Journal of Clinical Oncology ·Dena Battle, (unknown), Pavlos Msaouel, Martin H. Voss, Michael Staehler	1
4	Long-Term Follow-Up in Patients Undergoing Renal Mass Biopsy: Seeding is not Anecdotal 2023 ·Clinical Genitourinary Cancer ·Michael Staehler, Severin Rodler, (unknown), Christian G. Stief, (unknown), (unknown), Annika Herlemann	4
5	Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy. 2023 ·Journal of Clinical Oncology ·Michael Staehler, (unknown), Ulka N. Vaishampayan, Severin Rodler, (unknown), Dena Battle	2
6	The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921) 2022 ·Oncology Research and Treatment ·Yannic Volz, (unknown), Lennert Eismann, Friedrich Jokisch, Gerald Bastian Schulz, Boris Schlenker, Alexander Kretschmer, Michael Staehler, Stefan Boeck, Raphaela Waidelich, Alexander Büchner, Christian G. Stief, Severin Rodler	5
7	Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment 2021 ·Urologic Oncology Seminars and Original Investigations ·Annabel Spek, Anno Graser, Jozefina Casuscelli, Bernadett Szabados, Severin Rodler, Julian Marcon, Christian G. Stief, Michael Staehler	1
8	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma 2020 ·JCO Oncology Practice ·Cristiane Decat Bergerot, Dena Battle, Errol J. Philip, Paulo Gustavo Bergerot, Pavlos Msaouel, Allan Ben Smith, (unknown), Brian Shuch, Ithaar Derweesh, Eric Jonasch, Adam P. Stern, Sumanta K. Pal, Michael Staehler	17
9	730P Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe 2020 ·Annals of Oncology ·Giuseppe Procopio, Paul Hamberg, Pierre Bigot, Cristina Suárez, Philippe Barthélémy, (unknown), Cristina Masini, P. Gajate Borau, (unknown), Valérie Perrot, Michael Staehler	1
10	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio’s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print] 2019 ·European Urology Focus ·Rohann Correa, Alexander V. Louie, Nicholas G. Zaorsky, Eric J. Lehrer, Rodney J. Ellis, Lee Ponsky, Irving Kaplan, Anand Mahadevan, William Chu, Anand Swaminath, Raquibul Hannan, Hiroshi Onishi, Bin S. Teh, Alexander Muacevic, Simon S. Lo, Michael Staehler, Shankar Siva	1
11	Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT—correlation with microvascular density 2019 ·European Radiology ·Julian Marcon, Anno Graser, David Horst, Jozefina Casuscelli, Annabel Spek, Christian G. Stief, Maximilian F. Reiser, Johannes Rübenthaler, Alexander Büchner, Michael Staehler	69
12	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis 2018 ·Clinical Cancer Research ·Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev Pandha, Anup Patel, (unknown), Alain Ravaud	18
13	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib 2018 ·Clinical Cancer Research ·Brian I. Rini, Bernard Escudier, Jean-François Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Phillip G. Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J. Motzer, Alain Ravaud	45
14	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis 2018 ·European Urology Focus ·Saeed Dabestani, Christian Beisland, Grant D. Stewart, Karim Bensalah, Eirikur Guðmundsson, Thomas Lam, (unknown), Paimaun Zakikhani, Lorenzo Marconi, Sergio Fernandéz‐Pello, (unknown), Samuel P. Williams, Christian Torbrand, Thomas Powles, Erik van Werkhoven, Richard P. Meijer, Alessandro Volpe, Michael Staehler, Börje Ljungberg, Axel Bex	65
15	Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial 2018 ·Annals of Oncology ·Michael Staehler, Robert J. Motzer, Daniel J. George, Hardev Pandha, Frede Donskov, Bernard Escudier, (unknown), Anup Patel, (unknown), Helen Bhattacharyya, Krishnan Ramaswamy, Giovanni Zanotti, Xun Lin, Mariajosé Lechuga, Lucile Serfass, Jean Paty, Alain Ravaud	32
16	Long-term outcomes after resection of Stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest 2016 ·European Journal of Cardio-Thoracic Surgery ·Alexey Dashkevich, Erik Bagaev, Christian Hagl, Maximilian Pichlmaier, Maximilian Luehr, Vera von Dossow, Christian G. Stief, Paolo Brenner, Michael Staehler	7
17	A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN 2013 ·Annals of Oncology ·Bohuslav Melichar, Sergio Bracarda, В. Б. Матвеев, B. Yа. Alekseev, С. А. Иванов, A. V. Zyryаnov, Rasa Jančiauskienė, Eva Fernebro, Peter F.A. Mulders, Stuart Osborne, Sangeeta Jethwa, G. Mickisch, Martin Gore, R. Jeroen A. van Moorselaar, Michael Staehler, Nicolas Magné, Joaquim Bellmunt	24
18	Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation 2010 ·European journal of medical research ·Michael Staehler, Nicolas Haseke, Alexander Roosen, Thomas Städler, (unknown), Michael Siebels, Alexander Karl, (unknown)	30
19	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
20	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Cezary Szczylik, Thomas E. Hutson, Tomasz Demkow, Michael Staehler, Frédéric Rolland, Sylvie Négrier, Nicole Laferriere, Urban Scheuring, David Cella, Sonalee Shah, Ronald M. Bukowski	378

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact